[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1110651T1 - Παραγωγα της ν-'(1,5-διφαινυλ-1η- πυραζολ-3-υλ)μεθυλ σουλφοναμιδης με μια συγγενεια για τους υποδοχεις cb1 - Google Patents

Παραγωγα της ν-'(1,5-διφαινυλ-1η- πυραζολ-3-υλ)μεθυλ σουλφοναμιδης με μια συγγενεια για τους υποδοχεις cb1

Info

Publication number
CY1110651T1
CY1110651T1 CY20101100491T CY101100491T CY1110651T1 CY 1110651 T1 CY1110651 T1 CY 1110651T1 CY 20101100491 T CY20101100491 T CY 20101100491T CY 101100491 T CY101100491 T CY 101100491T CY 1110651 T1 CY1110651 T1 CY 1110651T1
Authority
CY
Cyprus
Prior art keywords
alkyl
unsubstituted
substituted
difinyl
methylyl
Prior art date
Application number
CY20101100491T
Other languages
English (en)
Inventor
Francis Barth
Christian Congy
Serge Martinez
Murielle Rinaldi-Carmona
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Publication of CY1110651T1 publication Critical patent/CY1110651T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Anesthesiology (AREA)

Abstract

Η παρούσα εφεύρεση έχει ως αντικείμενο ενώσεις οι οποίες ανταποκρίνονται στον χημικό τύπο (I) : Διαδικασία παρασκευής και εφαρμογή σε θεραπευτικές αγωγές στην οποία : το R1 αντιπροσωπεύει ένα (C1-C6)αλκυλ ∙ ένα (C3-C7) κυκλοαλκυλ μη υποκατεστημένο ή υποκατεστημένο μια ή περισσότερες φορές ∙ ένα (C3-C7) κυκλοαλκυλμεθυλ μη υποκατεστημένο ή υποκατεστημένο μια ή περισσότερες φορές ∙ ένα φαινυλ μη υποκατεστημένο ή υποκατεστημένο ∙ ένα βενζυλ μη υποκατεστημένο ή μονο- ή δις υποκατεστημένο ∙ ένα θειενυλ μη υποκατεστημένο ή υποκατεστημένο ∙ το R2 αντιπροσωπεύει ένα άτομο υδρογόνου ή ένα (C1-C3)αλκυλ ∙ το R3 αντιπροσωπεύει ένα άτομο υδρογόνου ή ένα (C1-C5)αλκυλ ∙ τα R4, R5, R6, R7, R8 και R9 αντιπροσωπεύουν το καθένα ανεξάρτητα ένα άτομο υδρογόνου, ένα άτομο αλογόνου, ένα (C1-C7)αλκυλ, ένα (C1-C5)αλκοξυ, μια ρίζα τριφθορομεθυλ ή μια ομάδα S(O)nAlk ∙ το n αντιπροσωπεύει 0, 1 ή 2 ∙ το Alk αντιπροσωπεύει ένα (C1-C4)αλκυλ. Διαδικασία παρασκευής και εφαρμογής στην θεραπευτική αγωγή.
CY20101100491T 2004-01-12 2010-06-03 Παραγωγα της ν-'(1,5-διφαινυλ-1η- πυραζολ-3-υλ)μεθυλ σουλφοναμιδης με μια συγγενεια για τους υποδοχεις cb1 CY1110651T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0400257A FR2864958B1 (fr) 2004-01-12 2004-01-12 Derive de n-[(1,5-diphenyl-1h-pyrazol-3-yl)methyl] sulfonamide, leur preparation et leur application en therapeutique.
EP05717379A EP1720837B1 (fr) 2004-01-12 2005-01-07 Derives de n-'(1,5-diphenyl-1h-pyrazol-3-yl)methyl sulfonamide avec une affinite pour les recepteurs cb1

Publications (1)

Publication Number Publication Date
CY1110651T1 true CY1110651T1 (el) 2015-06-10

Family

ID=34684951

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100491T CY1110651T1 (el) 2004-01-12 2010-06-03 Παραγωγα της ν-'(1,5-διφαινυλ-1η- πυραζολ-3-υλ)μεθυλ σουλφοναμιδης με μια συγγενεια για τους υποδοχεις cb1

Country Status (31)

Country Link
US (1) US7294645B2 (el)
EP (1) EP1720837B1 (el)
JP (1) JP4723514B2 (el)
KR (1) KR20060105050A (el)
CN (1) CN1910157A (el)
AR (1) AR047096A1 (el)
AT (1) ATE465995T1 (el)
AU (1) AU2005209441B2 (el)
CA (1) CA2551141C (el)
CR (1) CR8468A (el)
CY (1) CY1110651T1 (el)
DE (1) DE602005020907D1 (el)
DK (1) DK1720837T3 (el)
EC (1) ECSP066695A (el)
ES (1) ES2344850T3 (el)
FR (1) FR2864958B1 (el)
HR (1) HRP20100283T8 (el)
IL (1) IL176710A0 (el)
MA (1) MA28422B1 (el)
NO (1) NO20063621L (el)
NZ (1) NZ548442A (el)
PL (1) PL1720837T3 (el)
PT (1) PT1720837E (el)
RS (1) RS51365B (el)
RU (1) RU2366657C2 (el)
SI (1) SI1720837T1 (el)
TN (1) TNSN06203A1 (el)
TW (1) TWI323255B (el)
UA (1) UA85079C2 (el)
WO (1) WO2005073197A1 (el)
ZA (1) ZA200605657B (el)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030141B2 (en) * 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
FR2880023B1 (fr) * 2004-12-23 2007-02-23 Sanofi Aventis Sa Derives de n-[(4,5-diphenyl-3-alkyl-2-thienyl) methyl] amine leur preparation et leur application en therapeutique
FR2880890B1 (fr) * 2005-01-19 2007-03-30 Sanofi Aventis Sa Derives de n-[(4,5-diphenyl-2-thienyl)methyl]sulfonamide, leur preparation et leur application en therapeutique
FR2881744B1 (fr) 2005-02-09 2007-04-27 Sanofi Aventis Sa Derives de n-[(4,5-diphenyl-2-thienyl)methyl]amine, leur preparation et leur application en therapeutique
FR2894578B1 (fr) * 2005-12-12 2008-02-01 Sanofi Aventis Sa Derives heterocycliques, leur preparation et leur application en therapeutique.
FR2894579B1 (fr) * 2005-12-12 2008-01-18 Sanofi Aventis Sa Derives diaryltriazolmethylamine, leur preparation et leur application en therapeutique.
EP1829867A1 (en) * 2006-03-03 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Imidazole compounds having pharmaceutical activity towards the sigma receptor
FR2899899A1 (fr) * 2006-04-14 2007-10-19 Sanofi Aventis Sa Derives d'aminomethyl pyridine, leur preparation et leur application en therapeutique
EP1878723B1 (fr) * 2006-07-11 2010-05-26 Sanofi-Aventis Dérivés de N-[(1,5-diphényl-1H-pyrazol-3-yl)méthyl]sulfonamide antagonistes des récepteurs CB1 des cannabinoïdes
US7297710B1 (en) * 2006-07-12 2007-11-20 Sanofi-Aventis Derivatives of N-[(1,5-diphenyl-1H-pyrazol-3-yl)methyl]sulfonamide, their preparation and their application in therapeutics
JP2008019205A (ja) * 2006-07-12 2008-01-31 Sanofi-Aventis Ｎ−［（１，５−ジフェニル−１ｈ−ピラゾール−３−イル）メチル］スルホンアミド誘導体、その調製法および治療におけるその応用
WO2008062424A2 (en) * 2006-07-31 2008-05-29 Cadila Healthcare Limited Substituted 4,5-dihydro-1h-pyrazole derivatives as cannabinoid modulators
US7875647B2 (en) 2006-09-29 2011-01-25 Green Cross Corporation Heteroaryl-pyrazole derivatives as cannabinoid CB1 receptor antagonists
EP1911747A1 (en) * 2006-10-11 2008-04-16 Laboratorios del Dr. Esteve S.A. Sulfonamide substituted pyrazoline compounds, their preparation and use as CB1 modulators
FR2911136B1 (fr) * 2007-01-05 2009-02-20 Sanofi Aventis Sa Derives de n-(4-cyano-1h-pyrazol-3-yl)methylamine substitues leur preparation et leur application en therapeutique.
FR2919184A1 (fr) * 2007-07-26 2009-01-30 Sanofi Aventis Sa L'acide 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4- methylpyrazole-3-carboxylique, ses esters, ses sels pharmaceutiquement acceptables et leurs solvates pour leur utilisation comme medicament.
EP2885304B8 (en) * 2012-08-16 2016-12-07 Janssen Pharmaceutica NV Pyrrolopyrazoles as n-type calcium channel blockers
AU2013302468B2 (en) 2012-08-16 2017-08-24 Janssen Pharmaceutica Nv Substituted pyrazoles as N-type calcium channel blockers
MX2015008830A (es) * 2013-01-17 2015-10-14 Hoffmann La Roche Agonistas del receptor de oxitocina para el tratamiento de enfermedades del sistema nervioso central.
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
KR101685993B1 (ko) 2014-05-15 2016-12-13 한국과학기술연구원 전압개폐 칼슘이온채널 억제 활성화능을 갖는 ｎ-(피라졸릴메틸)아릴설폰아마이드 화합물 및 이를 포함하는 약학적 조성물
AU2017260706B2 (en) 2016-05-04 2023-05-11 Inmed Pharmaceuticals Inc. Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders
US20240000806A1 (en) * 2020-11-20 2024-01-04 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods and materials for inhibiting cb1 activity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.

Also Published As

Publication number Publication date
NO20063621L (no) 2006-10-10
MA28422B1 (fr) 2007-02-01
ATE465995T1 (de) 2010-05-15
CR8468A (es) 2007-03-06
HRP20100283T1 (hr) 2010-08-31
US20070021486A1 (en) 2007-01-25
SI1720837T1 (sl) 2010-08-31
CA2551141C (fr) 2011-06-07
RS51365B (en) 2011-02-28
KR20060105050A (ko) 2006-10-09
HRP20100283T8 (en) 2010-10-31
CA2551141A1 (fr) 2005-08-11
PL1720837T3 (pl) 2010-09-30
JP2007517839A (ja) 2007-07-05
ECSP066695A (es) 2006-10-31
ES2344850T3 (es) 2010-09-08
TNSN06203A1 (en) 2007-11-15
AU2005209441A1 (en) 2005-08-11
FR2864958B1 (fr) 2006-02-24
RU2366657C2 (ru) 2009-09-10
EP1720837A1 (fr) 2006-11-15
RU2006129297A (ru) 2008-02-20
AU2005209441B2 (en) 2010-12-23
FR2864958A1 (fr) 2005-07-15
IL176710A0 (en) 2006-10-31
TW200535135A (en) 2005-11-01
WO2005073197A1 (fr) 2005-08-11
EP1720837B1 (fr) 2010-04-28
UA85079C2 (en) 2008-12-25
US7294645B2 (en) 2007-11-13
NZ548442A (en) 2009-10-30
JP4723514B2 (ja) 2011-07-13
TWI323255B (en) 2010-04-11
DK1720837T3 (da) 2010-08-23
AR047096A1 (es) 2006-01-04
ZA200605657B (en) 2007-12-27
PT1720837E (pt) 2010-05-14
CN1910157A (zh) 2007-02-07
DE602005020907D1 (de) 2010-06-10

Similar Documents

Publication Publication Date Title
CY1110651T1 (el) Παραγωγα της ν-'(1,5-διφαινυλ-1η- πυραζολ-3-υλ)μεθυλ σουλφοναμιδης με μια συγγενεια για τους υποδοχεις cb1
CY1123308T1 (el) Αναστολεας ινωσης
CY1107008T1 (el) Παραγωγο βενζιμιδαζολης και χρηση ως ανταγωνιστου υποδοχεα aii
ATE496620T1 (de) 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
CY1118390T1 (el) Θεραπευτικος παραγων για τη φλεγμονωδη νοσο του εντερου
CY1106674T1 (el) Αζαδικυκλικοι ετεροκυκλοι σαν ρυθμιστες υποδοχεα κανναβινοειδους
ES2572189T3 (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogénesis
ME01421B (me) 5-supstituisani derivati kinazolinona kao protivtumorska sredstva
BRPI0612888A8 (pt) anilino-piridinotriazinas cíclicas
CY1105899T1 (el) Πυριδινοϋλοπιπepιδινες ως 5-ht1f αγωνιστες
CY1113099T1 (el) Παραγωγα (θειο)καρβαμοϋλ-κυκλοεξανιου ως ανταγωνιστες των υποδοχεων d3/d2
CY1111628T1 (el) Υποκατεστημενες ενωσεις δικυκλολακταμης
CY1106679T1 (el) Αζαδικυκλικες ετεροκυκλικες ενωσεις ως τροποποιητες κανναβινοειδους υποδοχεα
CY1112914T1 (el) Υποκατεστημενα παραγωγα ινδολυλ αλκυλ αμινης ως νεοι αναστολεις των αποακετυλασων ιστονης
CY1109015T1 (el) Διφαινυλ ενωσεις χρησιμες ως ανταγωνιστες μουσκαρινικου υποδοχεα
CY1114932T1 (el) Αντιπαρασιτικοι παραγοντες
EA201170096A1 (ru) Замещенные производные пиримидона
EA201100368A1 (ru) Амидные соединения, полезные в терапии
AR053340A1 (es) Derivados de trifluormetilbenzamida y sus usos terapeuticos
UY27685A1 (es) Indolil-urea derivados de tienopiridinas útiles como agentes antiangiogénicos, y procedimientos para su uso
UY30285A1 (es) Derivados de aminometilpirina, su preparacion y su aplicacion en terapéutica
EA201070321A1 (ru) Замещённые пиперазинил-пиразины и пиридины в качестве антагонистов рецепторов 5-нт
ATE447575T1 (de) Selektive spirocyclische glucocorticoid-rezeptor- modulatoren
TW200517387A (en) Compounds exhibiting thrombopoietin receptor agonism
CY1114378T1 (el) Μεθοδος χρησιμοποιησης συνδυασμου παραγωγου βενζοφαινονης ή αλατος αυτου και ανοσοκατασταλτικου παραγοντα, και φαρμακευτικη συνθεση που περιλαμβανει αυτα τα συστατικα